Search for Clinical Trial Results

Sponsored By

Cytomegalic Inclusion Disease - 21 Studies Found

Status Study
Completed Study Name: Certican® (Everolimus) Against Cytomegalovirus Disease in Renal Transplant Patients
Condition: Cytomegalovirus Disease
Date: 2009-01-23
Interventions:
  • Drug: Certican (everolimus) + valganciclovir

Completed Study Name: Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection
Condition: Cytomegalovirus Disease
Date: 2012-01-10
Interventions:
  • Drug: Valganciclovir Valcyte p
Completed Study Name: A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients
Condition: Cytomegalovirus Infections
Date: 2012-12-17
Interventions:
  • Drug: MCMV3068A Four doses of

Terminated Study Name: SUSTAIN: A Randomized, Double-Blind, Multicenter, Phase 3 Study of the Efficacy, Safety, and Tolerability of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease in CMV Seronegative Kidney Allograft Recipients
Condition: Cytomegalovirus Disease
Date: 2015-05-07
Interventions:
  • Drug: Brincidofovir Other Name
Completed Study Name: Quantiferon - Cytomegalovirus (CMV) and the Prediction of CMV Infection In High Risk Solid Organ Transplant Recipients
Condition: Cytomegalovirus Infection
Date: 2008-10-15
Completed Study Name: Evaluation of the PK and PD of Ganciclovir in Premature Infants Receiving Treatment for CMV Infection
Condition: Cytomegalovirus Infections
Date: 2012-05-17
Completed Study Name: Efficacy Study of Human Cytomegalovirus (HCMV) Hyperimmune Globulin to Prevent Congenital HCMV Infection
Condition: Cytomegalovirus Infection
Date: 2009-04-14
Interventions:
  • Drug: HCMV-specific hyperimmune globulin (Cytotect®)

Active, not recruiting Study Name: A French Cohort of Transplant Recipients With CMV Infection : Risk Factors for Antiviral Resistance in the Prophylaxis Era.
Condition: Transplant Recipients With CMV Infection
Date: 2014-02-14
Interventions: Biological: CMV Infection Routine follow-up (viral load, creatininaemia, neutrophil count, isolation of
Completed Study Name: gB/MF59 Vaccine in Preventing Cytomegalovirus Infection in Healthy Adolescent Females
Condition: Cytomegalovirus Infections
Date: 2005-08-19
Interventions:
  • Biological: MF-59 Microfluorid
Completed Study Name: Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
Condition: Cytomegalovirus Infections
Date: 2012-06-01
Interventions: Drug: Maribavir Tablet for oral administration
Next >>>